Список литературы

1. Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак щитовидной железы: современные подходы к диагностике и лечению. М.: ГЭОТАР-Медиа, 2009. 448 с.

2. Каприн А.Д., Старинский В.В., А.О. Шахзадова, Злокачественные новообразования в России в 2021 году (заболеваемость и смертность) - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России, - 2022. - илл. - 252 с.

3. Allelein, S., Ehlers, M., Morneau, C., Schwartz, K., Goretzki, P., Seppel, T., ... Schott, M. (2017). Measurement of Basal Serum Calcitonin for the Diagnosis of Medullary Thyroid Cancer. Hormone and Metabolic Research, 50(01), 23 - 28.

4. Матякин Е.Г., Подвязников С.О. Опухоли щитовидной железы. Онкология: справочник практикующего врача. Под ред. чл.-корр. РАН И.В. Поддубной. М.: МЕДпресс-информ, 2009. С. 177 - 185.

5. Бржезовский В.Ж. Опухоли щитовидной железы. Опухоли головы и шеи. 5-е изд., доп. и перераб. М.: Практическая медицина, 2013. С. 339 - 359.

6. Бельцевич Д.Г., Ванушко В.Э., Румянцев П.О. и др. Российские клинические рекомендации по диагностике и лечению высокодифференцированного рака щитовидной железы у взрослых. Эндокринная хирургия 2017; 1(11): 6 - 27.

7. Алиева С.Б., Алымов Ю.В., Кропотов М.А. и др. Рак щитовидной железы. Онкология. Клинические рекомендации. Под ред. М.И. Давыдова. М.: Издательская группа РОНЦ, 2015. С. 538 - 547.

8. Злокачественные опухоли головы и шеи. Под ред. Подвязникова С.О., Мудунова А.М., Болотина М.В. и др. Клинические рекомендации по лечению опухолей головы и шеи Общенациональной онкологической сети (США). М.: ООО "АБВ-пресс", 2019.

9. Онкология. Клинические рекомендации. Под ред. В.И. Чиссова. М.: ГЭОТАР-Медиа, 2006. С. 125 - 139.

10. Cooper D.S., Doherty G.M., Haugen B.R. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109 - 42.

11. McLeod D.S., Watters K.F., Carpenter A.D. et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012; 97: 2682 - 92. Available at: http://www.ncbi.nlm.nih. gov/pubmed/22622023.

12. Rinaldi S., Plummer M., Biessy C. et al. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst 2014; 106: dju097. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24824312.

13. Bonavita J.A., Mayo J., Babb J. et al. Pattern recognition of benign nodules at ultrasound of the thyroid: which nodules can be left alone? AJR Am J Roentgenol 2009; 193: 207 - 13. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19542415.

14. Alexander E.K., Cooper D. The importance, and important limitations, of ultrasound imaging for evaluating thyroid nodules. JAMA Intern Med 2013; 173: 1796 - 7. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23979653.

15. Friedrich-Rust M., Meyer G., Dauth N. et al. Interobserver agreement of Thyroid Imaging Reporting and Data System (TIRADS) and strain elastography for the assessment of thyroid nodules. PLoS One 2013; 8: e77927. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24205031.

16. Kamran S.C., Marqusee E., Kim M.I. et al. Thyroid nodule size and prediction of cancer. J Clin Endocrinol Metab 2013; 98: 564 - 70. Available at: http://www.ncbi. nlm.nih.gov/pubmed/23275525.

17. Yang J., Schnadig V., Logrono R., Wasserman P.G. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 2007; 111: 306 - 15. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/17680588.

18. DANESE, D., SCIACCHITANO, S., FARSETTI, A., ANDREOLI, M., & PONTECORVI, A. (1998). Diagnostic Accuracy of Conventional Versus Sonography-Guided Fine-Needle Aspiration Biopsy of Thyroid Nodules. Thyroid, 8(1), 15 - 21.

19. Trimboli, P., D'Aurizio, F., Tozzoli, R., & Giovanella, L. (2017). Measurement of thyroglobulin, calcitonin, and PTH in FNA washout fluids. Clinical Chemistry and Laboratory Medicine (CCLM), 55(7).

20. Cibas E.S., Ali S.Z. The 2017 Bethesda System For Reporting Thyroid Cytopathology. Thyroid 2017; 27: 1341 - 6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/29091573.

21. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)). Thyroid Carcinoma. Version 2.2022.

22. Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997; 174: 462 - 8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9374215.

23. Matsuzu K., Sugino K., Masudo K. et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg 2014; 38: 68 - 79. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24081532.

24. Francis G, Waguespack S, Bauer A, et al. American Thyroid Association Guidelines Task Force Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015 Jul; 25(7): 716 - 59. doi: 10.1089/thy.2014.0460

25. Danielle L., James MB, MCh. et al. Radioiodine Remnant Ablation for Differentiated Thyroid Cancer A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021; 147(6): 544 - 552. doi: 10.1001/jamaoto.2021.0288

26. Каприн А.Д. Терапевтическая радиология. Национальное руководство. М. - 2018 г. - С. 640 - 651.

27. Шуринов А.Ю., Крылов В.В., Бородавина Е.В. Радиойодаблация при раке щитовидной железы. Исторические и современные аспекты. Обзор литературы. Онкологический журнал: лучевая диагностика, лучевая терапия. 2021; 4(4): 9 - 19. https://doi.org/10.37174/2587-7593-2021-4-4-9-19

28. Filetti S, Durante C, Hartl D, et al. 2019. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019. Dec 1; 30(12): 1856 - 1883. doi: 10.1093/annonc/mdz400.

29. Vrachimis A, Riemann B, U, et al. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. Eur J Nucl Med Mol Imaging. 2016 Feb; 43(2): 224 - 231. doi: 10.1007/s00259-015-3223-2.

30. Gulec S, Ahuja S, Bernet V, et al. A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the EuropeanThyroid Association, the Society of Nuclear Medicineand Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. Thyroid. 2021 Jul; 31(7): 1009 - 1019. doi: 10.1089/thy.2020.0826.

31. Francis G, Waguespack S, Bauer A, et al. American Thyroid Association Guidelines Task Force Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid. 2015 Jul; 25(7): 716 - 59. doi: 10.1089/thy.2014.0460.

32. Biondi B., Cooper D.S. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20: 135 - 46. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20151821.

33. Brose M.S., Worden F.P., Newbold K.L., Guo M., Hurria A. Влияние возраста пациентов на эффективность и безопасность ленватиниба при лечении радиойодрефрактерного дифференцированного рака щитовидной железы в исследовании III фазы SELECT. Опухоли головы и шеи. 2018; 8(2): 39 - 52. https://doi.org/10.17650/2222-1468-2018-8-2-39-52.

34. Brose M.S., Panaseykin Y., Konda B., de la Fouchardiere C., Hughes B.G., Gianoukakis A.G., Park Y.J., Romanov I., Krzyzanowska M.K., Leboulleux S., Binder T.A., Dutcus C., Xie R., Taylor M.H. Рандомизированное исследование по оценке безопасности и эффективности двух дозировок ленватиниба - 18 и 24 мг - у пациентов с радиойодрефрактерным дифференцированным раком щитовидной железы. Опухоли головы и шеи. 2022; 12(1): 86 - 98. https://doi.org/10.17650/2222-1468-2022-12-1-86-98

35. Schlumberger, M., Tahara, M., Wirth, L. J., et al. (2015). Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. New England Journal of Medicine, 372(7), 621 - 630. doi: 10.1056/nejmoa1406470

36. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014; 384(9940): 319 - 328. doi: 10.1016/S0140-6736(14)60421-9.

37. Brose MS, Robinson B, Sherman SI, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021; 22(8): 1126 - 1138. doi: 10.1016/S1470-2045(21)00332,

38. Mosele, F., Remon, J., Mateo, J., et al (2020). Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. doi: 10.1016/j.annonc.2020.07

39. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018; 378(8): 731 - 739

40. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1 - 2 trials. Lancet Oncol. 2020; 21(2): 271 - 282. doi: 10.1016/S1470-2045(19)30691-6

41. Chiu A.C., Delpassand E.S., Sherman S.I. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997; 82: 3637 - 42. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9360519.

42. Expert Panel on Radiation Oncology-Bone Metastases, Lo S.S., Lutz S.T. et al. ACR Appropriateness Criteria (R) spinal bone metastases. J Palliat Med 2013; 16: 9 - 19. Available at: http://www.ncbi.nlm.nih.gov/pubmed/23167547.36.

43. Breelyn A Wilky, David M Loeb. Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP. Clin Exp Pharmacol. 2013 Jun; 3(3): 1000131. doi: 10.4172/2161-1459.1000131

44. Reyhaneh Manafi-Farid, Fardad Masoumi, Ghasemali Divband, Bahare Saidi, Bahar Ataeinia, Fabian Hertel, Gregor Schweighofer-Zwink, Agnieszka Morgenroth, Mohsen Beheshti. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain. J Clin Med. 2020 Aug 12; 9(8): 2622. doi: 10.3390/jcm9082622

45. Nicole M. , a, b Keith C. Bible, c, * and Bart L. Clarkea. Bone metastases in thyroid cancer. J Bone Oncol. 2020 Apr; 21: 100282. Published online 2020 Feb 19. doi: 10.1016/j.jbo.2020.100282

46. Fernanda Andrade, Danielle Probstner, Marcus Decnop, Daniel Bulzico, Denise Momesso, Rossana Corbo, Mario Vaisman, Fernanda Vaisman. The Impact of Zoledronic Acid and Radioactive Iodine Therapy on Morbi-Mortality of Patients with Bone Metastases of Thyroid Cancer Derived from Follicular Cells. Eur Thyroid J. 2019 Jan; 8(1): 46 - 55. doi: 10.1159/000493190. Epub 2018 Oct 3.

47. Juan Lv, Fu-Kun Chen, Chao Liu, Peng-Jie Liu, Zhi-Ping Feng, Li Jia, Zhi-Xian Yang, Fei Hou, Zhi-Yong Deng. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced pathway. Life Sci. 2020 Sep 1; 256: 117925. doi: 10.1016/j.lfs.2020.117925. Epub 2020 Jun 6.

48. Mosele, F., Remon, J., Mateo, J., et al (2020). Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology. doi: 10.1016/j.annonc.2020.07,

49. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022; 33(4): 406 - 415. doi: 10.1016/j.annonc.2021.12.014

50. Meric-Bernstam D, Rothe M, Garrett-Mayer E, et al. Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol. 40; 2022: 16 (abstract 3008). doi: 10.1200/JCO.2022.40.16_suppl.3008

51. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018; 378(8): 731 - 739,

52. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1 - 2 trials. Lancet Oncol. 2020; 21(2): 271 - 282. doi: 10.1016/S1470-2045(19)30691-6

53. Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid. 2021; 31(3): 337 - 386. doi: 10.1089/thy.2020.0944

54. Никифорович П.А., Поляков А.П., Слепцов И.В. и др. Таргетная терапия анапластического рака щитовидной железы. Опухоли головы и шеи 2022; 12(4): 20 - 25. DOI: 10.17650/2222-1468-2022-12-4-00-00

55. Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol. 2001; 27(3): 260 - 264. doi: 10.1053/ejso.2000.1098

56. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies. Clin Oncol. 2010; 22(6): 486 - 497. doi: 10.1016/j.clon.2010.03.013

57. Lee DY, Won J-K, Choi HS, et al. Recurrence and Survival After Gross Total Removal of Resectable Undifferentiated or Poorly Differentiated Thyroid Carcinoma. Thyroid. 2016; 26(9): 1259 - 1268. doi: 10.1089/thy.2016.0147

58. Pozdeyev N, Gay LM, Sokol ES, et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res. 2018; 24(13): 3059 - 3068. doi: 10.1158/1078-0432.CCR-18-0373

59. Rao SN, Zafereo M, Dadu R, et al. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid. 2017; 27(5): 672 - 681. doi: 10.1089/thy.2016.0395

60. Charles RP, Silva J, Iezza G, Phillips WA, McMahon M. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 2014; 12(7): 979 - 986. doi: 10.1158/1541-7786.MCR-14-0158-T

61. McFadden DG, Vernon A, Santiago PM, et al. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. Proc Natl Acad Sci USA. 2014; 111(16). doi: 10.1073/pnas.1404357111

62. Long G V., Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med. 2014; 371(20): 1877 - 1888. doi: 10.1056/nejmoa1406037

63. Nikiforovich PA, Rumiantsev PA, Sleptsov I V., et al. Treatment of BRAFv600e positive anaplastic thyroid carcinoma: Case report. Sib J Oncol. 2020; 19(5): 131 - 144. doi: 10.21294/1814-4861-2020-19-5-131-144

64. Long GV., Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017; 28(7): 1631 - 1639. doi: 10.1093/annonc/mdx176

65. Zhu C. Y. et al. Trends in the surgical management of known or suspected differentiated thyroid cancer at a single institution, 2010 - 2018//Thyroid. - 2020. - Т. 30. - N. 11. - С. 1639 - 1645.

66. Kim J. et al. Approach to Bethesda system category III thyroid nodules according to US-risk stratification//Endocrine Journal. - 2022. - Т. 69. - N. 1. - С. 67 - 74.

67. Paschke R. et al. The treatment of well-differentiated thyroid carcinoma//Deutsches International. - 2015. - Т. 112. - N. 26. - С. 452.

68. Cooper, D. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer/D. Cooper, G. Doherty, B. Haugen//Thyroid. - 2006. - Vol. 16, N 2. - P. 109 - 142. - doi: 10.1089/thy.2006.16.109.

69. Шуринов А.Ю., Бородавина Е.В., Крылов В.В. и др. Методические рекомендации по проведению радиойодтерапии при дифференцированном раке щитовидной железы и посттерапевтическому контролю. Опухоли головы и шеи 2024; 14(1): 83 - 95. DOI: 10.17650/2222-1468-2024-14-1-83-95

70. Чойнзонов Е.Л., Решетов И.В., Иванов С.А. и др. Проект клинических рекомендаций по диагностике и лечению дифференцированного рака щитовидной железы у взрослых пациентов. Эндокринная хирургия 2022; 16(2): 5 - 29.

71. Багрова С.Г., Басин Е.М., Валиев А.К., Деньгина Н.В., Копп М.В., Кутукова С.И. и соавт. Профилактика и лечение патологии костной ткани при злокачественных новообразованиях. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2, 2022 (том 12). 40 - 54.

72. Coleman R, et al. Bone health in cancer: ESMO Clinical Practice Guidelines Ann Oncol 2020: S0923-7534(20)39995-6

73. Veltri, A.; Bargellini, I.; Giorgi, L.; Almeida, P.A.M.S.; Akhan, O. CIRSE Guidelines on Percutaneous Needle Biopsy (PNB). Cardiovasc. Interv. Radiol. 2017, 40, 1501 - 1513. DOI: 10.1007/s00270-017-1658-5

74. Terezakis SA, Lee KS, Ghossein RA, Rivera M, Tuttle RM, Wolden SL, et al. Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center expe- rience. Int J Radiat Oncol Biol Phys. 2009; 73(3): 795 - 801.

75. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006 Aug; 91(8): 2892 - 9. doi: 10.1210/jc.2005-2838.

76. Wilhelm A, Conroy PC, Calthorpe L, Shui AM, Kitahara CM, Roman SA, Sosa JA. Disease-Specific Survival Trends for Patients Presenting with Differentiated Thyroid Cancer and Distant Metastases in the United States, 1992 - 2018. Thyroid. 2023 Jan; 33(1): 63 - 73. doi: 10.1089/thy.2022.0353. Epub 2022 Nov 18. PMID: 36413032;

77. Lancellotta V, Fanetti G, Monari F, Mangoni M, Mazzarotto R, Tagliaferri L, Gobitti C, Lodi Rizzini E, Talomo S, Turturici I, Paiar F, R, Jereczek-Fossa BA, Donato V, Vianello F. Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review. Radiol Med. 2022 Jun; 127(6): 681 - 689. doi: 10.1007/s11547-022-01489-2.

78. Sherman S.I., Tielens E.T., Sostre S. et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 629 - 34

79. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017 Mar; 27(3): 315 - 389. doi: 10.1089/thy.2016.0457. Erratum in: Thyroid. 2017 Sep; 27(9): 1212. doi: 10.1089/thy.2016.0457.correx. PMID: 28056690.

80. Dhillon-Smith RK, Boelaert K. Preconception Counseling and Care for Pregnant Women with Thyroid Disease. Endocrinol Metab Clin North Am. 2022 Jun; 51(2): 417 - 436. doi: 10.1016/j.ecl.2021.12.005. Epub 2022 May 4. PMID: 35662450.